Bromide

Bromide

SCHEMBL637596

Br.CCc1ccccc1C(N)(CC)CC

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.41
GABRB2 P47870 3/20 0.41
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
MGLL Q99685 1/20 0.34
IDO1 P14902 2/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PNMT P11086 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL643737 0.98 GABRA1 (0.43) GABRA1GABRB2MAPTALDH1A1MGLL
Iodide SCHEMBL1502860 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Hydrazine SCHEMBL10865940 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Benzene SCHEMBL29130110 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Fluoride SCHEMBL1502835 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Water SCHEMBL187638 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Water SCHEMBL1973854 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Hydrochloric Acid SCHEMBL77688 0.96 GABRA1 (0.41) GABRA1GABRB2MAPTALDH1A1MGLL
Cyanide SCHEMBL4048234 0.94 GABRA1 (0.40) GABRA1GABRB2MAPTALDH1A1MGLL
Alcohol SCHEMBL28273112 0.90 GABRA1 (0.42) GABRA1GABRB2MAPTALDH1A1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 985 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874616-B Organic intermediate and preparation method and application thereof 四川美域高生物医药科技有限公司 2025-05-30 CN claimed
US-20250163010-A1 PROCESSES FOR THE PREPARATION OF N-(1-METHYLCYCLOPROPYL)-2-(3-PYRIDINYL)-2H-INDAZOLE-4-CARBOXAMIDE AND INTERMEDIATES THEREOF FMC CORP (US) 2025-05-22 US claimed
CN-119874616-A Novel organic intermediate and preparation method and application thereof 四川美域高生物医药科技有限公司 2025-04-25 CN claimed
CN-119504719-A Synthesis method of 3-ethyl-3- [ (2-oxiranylmethoxy) methyl ] oxetane 湖北荆洪生物科技股份有限公司 2025-02-25 CN claimed
CN-119504660-A Method for preparing 3,3' - [1, 4-butyl bis (oxymethylene) ] -bis- (3-ethyl) oxetane 湖北荆洪生物科技股份有限公司 2025-02-25 CN claimed
CN-119350225-A Synthesis method of hydrogen storage material N-ethyl carbazole 连云港海迪化工科技有限公司 2025-01-24 CN claimed
CN-119081437-A Artificial board based on soybean-based adhesive and agricultural waste and preparation method thereof 华南农业大学 2024-12-06 CN claimed
CN-118715213-A Process for preparing N- (1-methylcyclopropyl) -2- (3-pyridinyl) -2H-indazole-4-carboxamide and intermediates thereof FMC公司 2024-09-27 CN claimed
CN-115572229-B Preparation method of polymerizable photoinitiator based on alpha-hydroxyketone 江苏三木化工股份有限公司 2024-09-13 CN claimed
CN-116003965-B Prepreg toughening layer 中国石油化工股份有限公司 2024-07-23 CN claimed
US-6515128-B2 Dissolving 6-hydroxy-3,4-dihydroquinolinone and a base in water; dissolving a 1-cyclohexyl-5- (4-halobutyl)-tetrazole in water-immiscible solvent, mixing aqueous phase and organic phase in presence of phase transfer catalyst; recovering TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-02-04 US claimed
US-20020099213-A1 Processes for preparing cilostazol TEVA PHARMACEUTICALS USA, INC. 2002-07-25 US claimed
WO-2002014283-A1 PROCESSES FOR PREPARING CILOSTAZOL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2002-02-21 WO claimed
US-5929233-A HALOGENATION OF ALLENYL BETA-LACTAM IN PRESENCE OF SULFINATE ION OR THIOLATE ION CAPTURING AGENT OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1999-07-27 US claimed
US-4889927-A REACTING ACYL-SUBSTITUTED GLYCOSE WITH ALKALI METAL HYDRIDE, HYDROLYSIS JUJO PAPER CO., LTD. (JP) 1989-12-26 US claimed
EP-0004570-B1 THIOL ESTERS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR PREPARING CEPHALOSPORIN COMPOUNDS USING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1982-04-14 EP claimed
US-4293702-A FROM 2-ALKOXYBENZOTHIAZOLES; CATALYST OF TERTIARY AMINE, QUATERNARY AMMONIUM COMPOUND OR DIALKYL SULFATE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-10-06 US claimed
EP-0004570-A1 Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1979-10-17 EP claimed
US-4144264-A Process for producing a 3-methyl-2-(4-halophenyl)butyronitrile SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-03-13 US claimed
US-4012428-A Method for preparing 3-methyl-2-(4-halogenophenyl)-butyronitrile SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-03-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099213-A1 Processes for preparing cilostazol PDE3A, PDE12, PDE5A GABRA1 2891/4885GABRB2 4041/4885MAPT 3372/4885
US-20250163010-A1 PROCESSES FOR THE PREPARATION OF N-(1-METHYLCYCLOPROPYL)-2-(3-PYRIDINYL)-2H-INDAZOLE-4-CARBOXAMIDE AND INTERMEDIATES THEREOF ACHE, CYP4B1, CYP3A4 GABRA1 1549/4885GABRB2 1584/4885MAPT 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.